Shots:
Accord BioPharma has launched Filkri, a biosimilar version of Neupogen (filgrastim), in the US following the FDA approval in Jan 2026
Filkri was approved based on data showing its similarity to Neupogen, with no clinically meaningful differences. It is available in 300mcg/0.5mL & 480mcg/0.8mL PFS presentations, with pack sizes of one or 10 PFS…
